Tethys Bioscience develops the Tethys PreDx™ Diabetes Risk Score (DRS), a multimarker blood test that identifies patients at high risk of developing type 2 diabetes within five years. The test is designed to pinpoint the 10–20% of individuals at the highest near-term risk to help target intervention. The company raised new capital to support expanded commercialization of the PreDx DRS. The financing comprised both venture capital and a working capital loan, bringing additional resources to its Series D. Following the latest financings, the company’s Series D has reached a total of $48M. The company is based in Emeryville, California. Tethys Bioscience, based in Emeryville, CA, develops blood tests to support identification of chronic diseases, with a focus on diabetes. Its core product is the PreDx™ Diabetes Risk Score (DRS), a blood test that helps clinicians identify patients at highest risk of developing type 2 diabetes within five years. The company has secured external financing to support commercialisation of the PreDx DRS. Tethys closed a $25M Series D to advance its go-to-market efforts for the product. As part of the financing, an investor representative joined the company’s board, indicating investor engagement in governance.

Total raised

$58M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Jul 2010